<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="59000"><DrugName>asapiprant</DrugName><DrugNamesKey><Name id="43013559">asapiprant</Name></DrugNamesKey><DrugSynonyms><Name><Value>prostaglandin D2 receptor antagonist (allergy), Shionogi</Value></Name><Name><Value>S-555739</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>asapiprant</Value><Types><Type>INN</Type></Types></Name><Name><Value>932372-01-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19898">Shionogi &amp; Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="19898">Shionogi &amp; Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="59000" type="Drug"><TargetEntity id="466914" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="19898" type="Company"><TargetEntity id="4295876951" type="organizationId">Shionogi &amp; Co Ltd</TargetEntity></SourceEntity><SourceEntity id="12" type="ciIndication"><TargetEntity id="10001708" type="MEDDRA"></TargetEntity><TargetEntity id="1180" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3201" type="ciIndication"><TargetEntity id="D012221" type="MeSH"></TargetEntity><TargetEntity id="-1764444025" type="omicsDisease"></TargetEntity><TargetEntity id="299" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3202" type="ciIndication"><TargetEntity id="D006255" type="MeSH"></TargetEntity><TargetEntity id="1184" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="12">Allergy</Indication><Indication id="3201">Perennial allergic rhinitis</Indication><Indication id="3202">Seasonal allergic rhinitis</Indication></IndicationsSecondary><ActionsPrimary><Action id="522">PGD2 antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-09-27T09:01:44.000Z</LastModificationDate><ChangeDateLast>2017-02-08T00:00:00.000Z</ChangeDateLast><AddedDate>2007-12-20T13:35:45.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19898" linkType="Company"&gt;Shionogi&lt;/ulink&gt; was developing asapiprant (S-555739), a prostaglandin D2 receptor antagonist, for the potential oral treatment of allergy, including perennial allergic rhinitis and seasonal allergic rhinitis  [&lt;ulink linkID="862693" linkType="Reference"&gt;862693&lt;/ulink&gt;], [&lt;ulink linkID="860460" linkType="Reference"&gt;860460&lt;/ulink&gt;], [&lt;ulink linkID="862692" linkType="Reference"&gt;862692&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2013, a phase III trial in seasonal allergic rhinitis was initiated in Japan [&lt;ulink linkID="1358152" linkType="Reference"&gt;1358152&lt;/ulink&gt;]; in August 2013, negative data were reported. At that time, a Japanese phase III  was planned in perennial allergic rhinitis  [&lt;ulink linkID="1462289" linkType="Reference"&gt;1462289&lt;/ulink&gt;]. In July 2012, a phase IIa study was initiated in patients with seasonal allergic rhinitis in the US [&lt;ulink linkID="1313471" linkType="Reference"&gt;1313471&lt;/ulink&gt;], [&lt;ulink linkID="1313485" linkType="Reference"&gt;1313485&lt;/ulink&gt;]. However, by February 2017, development had been discontinued [&lt;ulink linkID="1897299" linkType="Reference"&gt;1897299&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2013, a dose-finding trial was planned and would be conducted outside of Japan [&lt;ulink linkID="1393311" linkType="Reference"&gt;1393311&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2013, a randomized, double-blind, parallel-assignment phase III trial  (JapicCTI-132046) began in Japan  in patients with seasonal allergic rhinitis associated with Japanese cedar pollinosis. Patients would receive high- or low-dose   asapiprant in combination with an antihistamine, high-dose monotherapy asapiprant, monotherapy antihistamine, or placebo [&lt;ulink linkID="1358152" linkType="Reference"&gt;1358152&lt;/ulink&gt;]. Initial data presented in August 2013 showed that the study did not meet its primary endpoint, as there was no difference in total symptom score between asapiprant and antihistamine, and antihistamine alone, although there was a significant difference in the total of nasal and ocular symptom scores; the company noted that there had been a drastic reduction in pollen levels after patient entry with resultant large improvements in scores in all treatment groups [&lt;ulink linkID="1462289" linkType="Reference"&gt;1462289&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;by October 2011, a phase IIb trial had begun in Japan [&lt;ulink linkID="1236126" linkType="Reference"&gt;1236126&lt;/ulink&gt;]. In June 2012, initial data were reported. Data showed that a combination  of asapiprant plus antihistamine therapy exhibited reproducibly significant effect when  compared to monotherapy antihistamine [&lt;ulink linkID="1301123" linkType="Reference"&gt;1301123&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, a double-blind, placebo- and active-controlled phase IIa study (&lt;ulink linkID="89588" linkType="Protocol"&gt;NCT01651871&lt;/ulink&gt;, 1210D1526) was initiated in an expected 750 patients with seasonal allergic rhinitis in the US. The trial would evaluate the change in reflective total nasal symptom score in patients treated with asapiprant plus &lt;ulink linkID="2752" linkType="Drug"&gt;cetirizine&lt;/ulink&gt; compared to cetirazine alone [&lt;ulink linkID="1313485" linkType="Reference"&gt;1313485&lt;/ulink&gt;]. By February 2013, the trial had been completed [&lt;ulink linkID="1366666" linkType="Reference"&gt;1366666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2009, phase IIa studies in Japan had begun [&lt;ulink linkID="1030673" linkType="Reference"&gt;1030673&lt;/ulink&gt;]. In October 2009, a double-blind, phase II study (JapicCTI-090875) was initiated in patients with perennial allergic rhinitis, to assess the safety and efficacy of asapiprant. The study was completed in March 2010 [&lt;ulink linkID="1204263" linkType="Reference"&gt;1204263&lt;/ulink&gt;]; by June 2012, data from the trial had shown that the combination (asapiprant plus antihistamine) therapy and monotherapy (antihistamine) showed suppressive effects against symptoms of allergic rhinitis [&lt;ulink linkID="1301123" linkType="Reference"&gt;1301123&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I studies&lt;/subtitle&gt;In August 2011, a US IND filing was in preparation [&lt;ulink linkID="1211492" linkType="Reference"&gt;1211492&lt;/ulink&gt;], [&lt;ulink linkID="1211487" linkType="Reference"&gt;1211487&lt;/ulink&gt;]. By November 2011, phase I trials had begun in the US [&lt;ulink linkID="1211487" linkType="Reference"&gt;1211487&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By July 2008, a European phase I trial had been initiated [&lt;ulink linkID="929382" linkType="Reference"&gt;929382&lt;/ulink&gt;]. in October 2011, proof-of mechanism studies were ongoing in Europe [&lt;ulink linkID="1236126" linkType="Reference"&gt;1236126&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2008, a Japanese, phase I, single-dose study was underway. A multiple-dose study and a nasal challenge  study were due to start later that year [&lt;ulink linkID="897288" linkType="Reference"&gt;897288&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By November 2007, the company had selected asapiprant for further development, due to a better activity profile and pharmacokinetics than &lt;ulink linkID="16729" linkType="Drug"&gt;S-5751&lt;/ulink&gt; [&lt;ulink linkID="862692" linkType="Reference"&gt;862692&lt;/ulink&gt;], [&lt;ulink linkID="897288" linkType="Reference"&gt;897288&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="12">Allergy</Indication><StatusDate>2017-02-02T00:00:00.000Z</StatusDate><Source id="1897299" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate>2017-02-02T00:00:00.000Z</StatusDate><Source id="1897299" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate>2017-02-02T00:00:00.000Z</StatusDate><Source id="1897299" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate>2017-02-02T00:00:00.000Z</StatusDate><Source id="1897299" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>2011-08-01T00:00:00.000Z</StatusDate><Source id="1211492" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>2009-08-03T00:00:00.000Z</StatusDate><Source id="1030673" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>2011-10-31T00:00:00.000Z</StatusDate><Source id="1236126" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>2008-07-29T00:00:00.000Z</StatusDate><Source id="929382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate>2012-07-31T00:00:00.000Z</StatusDate><Source id="1313485" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3201">Perennial allergic rhinitis</Indication><StatusDate>2009-09-13T00:00:00.000Z</StatusDate><Source id="1204263" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><StatusDate>2013-01-19T00:00:00.000Z</StatusDate><Source id="1358152" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>2007-11-06T00:00:00.000Z</StatusDate><Source id="860460" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>2008-03-18T00:00:00.000Z</StatusDate><Source id="897288" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01609"><Name>Prostanoid receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CC(C)Oc1ccc(cc1)S(=O)(=O)N2CCN(CC2)c3ccc(c(c3)OCC(=O)O)c4ncco4</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1606482" number="WO-2008123349" title="Method for producing N-phenyl-N'-phenylsulfonylpiperazine derivative"/><PatentFamily id="2499365" number="WO-2013047725" title="Drug for the treatment of allergic rhinitis comprising PGD2 antagonist and histamine antagonist"/><PatentFamily id="2599084" number="WO-2013147118" title="N-phenyl-N'-phenylsulfonylpiperazine derivative and method for producing intermediate for same"/><PatentFamily id="3106587" number="WO-2016006621" title="PGD2-antagonist-containing medicine for treatment of symptoms associated with allergic diseases"/><PatentFamily id="953810" number="WO-2007037187" title="Sulfonamide derivative having PGD&lt;sub&gt;2&lt;/sub&gt; receptor antagonistic activity"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shionogi &amp; Co Ltd" id="19898"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>